Alembic Pharmaceuticals Gains Approval for Generic Antifungal Solution
Alembic Pharmaceuticals has received FDA approval to market a generic version of an antifungal medication, Efinaconazole Topical Solution. This approval allows them to compete in a market estimated at USD 500 million. Despite the announcement, Alembic's shares saw a decrease on the BSE.
- Country:
- India
Alembic Pharmaceuticals announced it has secured US FDA approval to market a generic antifungal drug, Efinaconazole Topical Solution.
The drug is approved for treating toenail onychomycosis caused by specific fungi and is therapeutically equivalent to Jublia Topical Solution.
The approval positions Alembic in a lucrative USD 500 million market, but its shares decreased slightly on the BSE.
Advertisement
ALSO READ
-
USFDA Form 483 Issued to Alkem Laboratories: Six Observations Noted at Chakan Unit
-
Piramal Pharma's Telangana Plant Receives USFDA Observations: Next Steps
-
Akums Drugs & Pharmaceuticals Surges with 29.5% Profit Jump in Q3
-
Torrent Pharmaceuticals Q3 profit up 26 pc at Rs 635 cr
-
India's nutraceutical sector set to grow tenfold over pharmaceuticals: FSSAI official
Google News